MAP3K20: A Potential Drug Target for Neurodegenerative Diseases

Target Name: MAP3K20

NCBI ID: G51776

MAP3K20

MAP3K20: A Potential Drug Target for Neurodegenerative Diseases

MAP3K20, also known as Mitogen-activated protein kinase kinase MLT, is a protein that plays a crucial role in cellular signaling. It is a key regulator of the MAPK/ERK signaling pathway, which is involved in a wide range of cellular processes, including cell growth, differentiation, and survival.

MAP3K20 is a 21-kDa protein that is expressed in various tissues and cell types. It is highly conserved, with a calculated pI of 11.5 and a predicted localization in the cytoplasm. The protein is associated with the endoplasmic reticulum and can be detected in the cell cytosol using an optimized laser capture microdissection assay.

MAP3K20 is involved in a number of cellular processes, including cell signaling, cell division, and stress response. It is a potent inhibitor of the MAPK/ERK signaling pathway, which is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival. The MAPK/ERK signaling pathway is a well-established target for drug development, with a number of inhibitors currently in use, including those that target MAPK3, MAPK4, and ERK1/2.

MAP3K20 has also been shown to play a role in the regulation of cell division. It is a negative regulator of the cyclin D1-CDK4 complex, which is involved in the regulation of cell cycle progression. The loss of MAP3K20 has been shown to lead to increased cell cycle progression and a higher risk of cancer.

MAP3K20 is also involved in the regulation of cellular stress response. It is a positive regulator of the HSP70 gene, which is involved in the regulation of protein homeostasis and stress response. The HSP70 gene is activated in response to cellular stress, and MAP3K20 plays a role in the regulation of its expression.

MAP3K20 is a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its inhibition has been shown to be effective in a variety of models, including cell culture and animal models of disease. For example, a MAP3K20 inhibitor has been shown to be effective in the treatment of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its potential therapeutic applications, MAP3K20 is also a valuable biomarker for a variety of diseases. Its expression is often increased in diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The levels of MAP3K20 have also been shown to be useful for the diagnosis of certain diseases, such as neurodegenerative diseases.

In conclusion, MAP3K20 is a protein that plays a crucial role in cellular signaling. Its inhibition has been shown to be effective in a variety of models, including the treatment of neurodegenerative diseases. Its potential as a drug target and biomarker make it an attractive target for further research and development.

Protein Name: Mitogen-activated Protein Kinase Kinase Kinase 20

Functions: Stress-activated component of a protein kinase signal transduction cascade that promotes programmed cell death in response to various stress, such as ribosomal stress, osmotic shock and ionizing radiation (PubMed:10924358, PubMed:11836244, PubMed:12220515, PubMed:14521931, PubMed:15350844, PubMed:15737997, PubMed:18331592, PubMed:20559024, PubMed:32610081, PubMed:32289254, PubMed:35857590, PubMed:26999302). Acts by catalyzing phosphorylation of MAP kinase kinases, leading to activation of the JNK (MAPK8/JNK1, MAPK9/JNK2 and/or MAPK10/JNK3) and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways (PubMed:11042189, PubMed:11836244, PubMed:12220515, PubMed:14521931, PubMed:15172994, PubMed:15737997, PubMed:32610081, PubMed:32289254, PubMed:35857590). Activates JNK through phosphorylation of MAP2K4/MKK4 and MAP2K7/MKK7, and MAP kinase p38 gamma (MAPK12) via phosphorylation of MAP2K3/MKK3 and MAP2K6/MKK6 (PubMed:11836244, PubMed:12220515). Involved in stress associated with adrenergic stimulation: contributes to cardiac decompensation during periods of acute cardiac stress (PubMed:15350844, PubMed:21224381, PubMed:27859413). May be involved in regulation of S and G2 cell cycle checkpoint by mediating phosphorylation of CHEK2 (PubMed:15342622)

The "MAP3K20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP3K20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets